Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/794
Title: Histological and extended clinical outcomes following ABO-incompatible renal transplantation without splenectomy or Rituximab.
Epworth Authors: Cohney, Solomon (Shlomo)
Other Authors: Chow, Kevin
Flint, Shaun
Shen, Angeline
Landgren, Anthony
Finlay, Moira
Murugasu, Anand
Masterson, Rosemary
Hughes, Peter
Keywords: UroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australia
Department of Nephrology, Epworth HealthCare, Richmond, Victoria, Australia.
Department of Gastroenterology, Epworth HealthCare, Richmond, Victoria, Australia.
Kidney Transplantation
Transplantation, Renal
Rituximab
Antibodies
Graft Survival
Immunosuppression
Biopsy
Splenectomy
Issue Date: 2016
Publisher: Wolters Kluwer
Citation: Transplantation. 2016 Aug 5. [Epub ahead of print]
Abstract: BACKGROUND: Excellent short-term results have been reported in ABO-incompatible renal transplant recipients (ABOi) managed solely with antibody removal and conventional immunosuppression. However, long-term clinical outcomes with this regimen and predictive information from protocol biopsies is lacking. METHODS: We compared outcome data in ABOi and ABO compatible (ABOc) recipients receiving this regimen approximately 4 years posttransplant, and histology from biopsies approximately 12 month posttransplant. RESULTS: Patient and graft survival amongst 54 ABOi recipients were 98.1% and 90.7% respectively at 4 years. Graft function was similar between ABOi (creatinine 140.3 μmol/L) and ABOc recipients (creatinine 140.2 μmol/L) (p=0.99), with no significant change over the study period in either group (Δcreatinine -0.83 vs 6.6 μmol/L) (p=0.59). There was no transplant glomerulopathy (TGP) in biopsies from either group. Interstitial fibrosis and tubular atrophy (IF/TA) was present in 7/25 (28%) ABOi compared with 7/34 (20.6%) ABOc (p=0.52). Progression of IF/TA from implantation was noted in 6/25 (24%) ABOi and 6/34 (17.6%) ABOc respectively. C4d staining without antibody mediated rejection (AbMR) was present in 13/25 (52%) of early posttransplant biopsies from ABOi recipients by immunohistochemistry, but in only 4/25 (16%) at 12 months. CONCLUSIONS: ABOi performed with antibody removal and conventional immunosuppression continues to provide excellent patient and graft survival, and stable renal function over 4 years. Coupled with absent TGP and low rates of progressive IF/TA on earlier biopsies, this suggests that ABOi with conventional immunosuppression and antibody removal, without rituximab or splenectomy, can achieve long-term outcomes comparable to ABO compatible transplantation.
URI: http://hdl.handle.net/11434/794
DOI: 10.1097/TP.0000000000001415
PubMed URL: http://www.ncbi.nlm.nih.gov/pubmed/27495772
ISSN: 0041-1337
Journal Title: Transplantation.
Type: Journal Article
Affiliated Organisations: Departments of Nephrology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Departments of Anatomical Pathology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia.
Departments of Medicine, University of Melbourne, Parkville, Victoria, Australia.
Division of Immunology, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Department of Nephrology, Western Hospital, Sunshine/Footscray, Victoria, Australia.
Type of Clinical Study or Trial: Comparative Study
Appears in Collections:UroRenal, Vascular

Files in This Item:
There are no files associated with this item.


Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.